Progyny, Inc.

NasdaqGS:PGNY Rapporto sulle azioni

Cap. di mercato: US$1.9b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Progyny Gestione

Gestione criteri di controllo 4/4

Progyny's Il CEO è Pete Anevski, nominato in Jan2022, e ha un mandato di 2.58 anni. la retribuzione annua totale è $ 1.09M, composta da 45.7% di stipendio e 54.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.16% delle azioni della società, per un valore di $ 3.10M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.6 anni e 7.4 anni.

Informazioni chiave

Pete Anevski

Amministratore delegato

US$1.1m

Compenso totale

Percentuale dello stipendio del CEO45.7%
Mandato del CEO2.6yrs
Proprietà del CEO0.2%
Durata media del management2.6yrs
Durata media del Consiglio di amministrazione7.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Progyny: Downgrading As Uncertainties Increase

Aug 15

Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing

Aug 11
Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing

At US$27.79, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?

Jul 20
At US$27.79, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?

Progyny: Recent Stock Decline Provides Buying Opportunity

Jul 12

Progyny's (NASDAQ:PGNY) Returns Have Hit A Wall

Jun 23
Progyny's (NASDAQ:PGNY) Returns Have Hit A Wall

Progyny: At This Price, Secular Tailwinds Are Too Compelling To Ignore

Jun 10

Progyny: No Change To Long-Term Outlook

Jun 04

Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price

Apr 29
Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price

Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

Apr 03
Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

Progyny: Long-Term Outlook Remains Positive, Reiterate Buy

Mar 15

Progyny: Long-Term Thesis Still Intact

Mar 09

Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher

Mar 01
Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher

Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable

Jan 07
Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Dec 11
Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Nov 08
Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Aug 24
Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital

Aug 06
There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital

Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital

May 06
Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital

When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?

Jan 25
When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?

Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue

Dec 12
Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue

Is It Time To Consider Buying Progyny, Inc. (NASDAQ:PGNY)?

Oct 18
Is It Time To Consider Buying Progyny, Inc. (NASDAQ:PGNY)?

Progyny Stock Should Deliver Superior Returns For Investors

Aug 05

Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Jul 27
Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Pete Anevski rispetto agli utili di Progyny?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

US$63m

Mar 31 2024n/an/a

US$61m

Dec 31 2023US$1mUS$500k

US$62m

Sep 30 2023n/an/a

US$52m

Jun 30 2023n/an/a

US$49m

Mar 31 2023n/an/a

US$43m

Dec 31 2022US$69mUS$500k

US$30m

Sep 30 2022n/an/a

US$42m

Jun 30 2022n/an/a

US$46m

Mar 31 2022n/an/a

US$56m

Dec 31 2021US$786kUS$425k

US$66m

Sep 30 2021n/an/a

US$90m

Jun 30 2021n/an/a

US$78m

Mar 31 2021n/an/a

US$58m

Dec 31 2020US$910kUS$425k

US$46m

Sep 30 2020n/an/a

US$3m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$5mUS$375k

-US$9m

Sep 30 2019n/an/a

-US$6m

Jun 30 2019n/an/a

US$1m

Mar 31 2019n/an/a

-US$4m

Dec 31 2018US$682kUS$325k

-US$6m

Compensazione vs Mercato: La retribuzione totale di Pete ($USD 1.09M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.62M ).

Compensazione vs guadagni: La retribuzione di Pete è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Pete Anevski (57 yo)

2.6yrs

Mandato

US$1,093,512

Compensazione

Mr. Peter Anevski, also known as Pete, has been Chief Executive Officer and Director of Progyny, Inc. since January 2022 and had been its President since June 2019 until December 31, 2021 and was its Chief...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
David Schlanger
Executive Chairman7.4yrsUS$513.57k0.055%
$ 1.0m
Peter Anevski
CEO & Director2.6yrsUS$1.09m0.16%
$ 3.1m
Michael Sturmer
President2.6yrsUS$1.49m0.064%
$ 1.2m
Mark Livingston
Chief Financial Officer3.9yrsUS$1.40m0.052%
$ 1.0m
Allison Swartz
Executive VP1.8yrsUS$546.22k0.016%
$ 301.3k
Steven Leist
Chief Technology Officerless than a yearNessun datoNessun dato
James Hart
Vice President of Investor Relationsno dataNessun datoNessun dato
Risa Fisher
Chief Marketing Officerno dataNessun datoNessun dato
Cassandra Pratt
Chief Human Resources Officerno dataNessun datoNessun dato
Julie Stadlbauer
Chief Business Development Officer2.6yrsNessun datoNessun dato
Janet Choi
Member of the Medical Advisory Board & Chief Medical Officer1.3yrsNessun datoNessun dato
Arielle Bogorad
Senior Vice President of Employer Market Strategy2.3yrsNessun datoNessun dato

2.6yrs

Durata media

57yo

Età media

Gestione esperta: Il team dirigenziale di PGNY è considerato esperto (durata media dell'incarico 2.6 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
David Schlanger
Executive Chairman7.4yrsUS$513.57k0.055%
$ 1.0m
Peter Anevski
CEO & Director2.6yrsUS$1.09m0.16%
$ 3.1m
Janet Choi
Member of the Medical Advisory Board & Chief Medical Officerno dataNessun datoNessun dato
Norman Payson
Independent Director7.7yrsUS$567.30k0.45%
$ 8.6m
Fred Cohen
Independent Director9.4yrsUS$583.35k0.013%
$ 257.0k
Beth Seidenberg
Lead Independent Director14.3yrsUS$653.39k0.29%
$ 5.5m
Kevin Gordon
Independent Director4.8yrsUS$518.30k0.0069%
$ 131.4k
Jeffrey Park
Independent Director4.8yrsUS$606.88k0.013%
$ 257.0k
Alan Copperman
Member of the Medical Advisory Boardno dataNessun datoNessun dato
Barry Behr
Member of Medical Advisory Boardno dataNessun datoNessun dato
Brad Kolb
Member of Medical Advisory Boardno dataNessun datoNessun dato
Gerard Letterie
Member of Medical Advisory Boardno dataNessun datoNessun dato

7.4yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PGNY sono considerati esperti (durata media dell'incarico 7.4 anni).